Clinical trials: MPM
Malignant Pleural Mesothelioma (MPM)
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM.
- Trial name
- NCT04577326
- Testing
- cyclophosphamide, CAR T cells
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid…
- Conditions
- Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
- Trial name
- NCT07713732
- Testing
- TLN-499, Venetoclax
- Where
- 3 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Treeline Biosciences, Inc.
MPM
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with pemetrexed and platinum as first line treatment for MPM.
- Trial name
- NCT05918107
- Testing
- PM8002, Pemetrexed, Cisplatin
- Where
- 16 sites in China
- Volunteers
- 31 people
- Sponsor
- Biotheus Inc.
Malignant Pleural Mesothelioma (MPM)
Multidimensional Omics Analysis in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare and incurable cancer. Most patients are diagnosed with unresectable disease for which treatment options are limited.
- Trial name
- OMIM (NCT07561190)
- Where
- 4 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Solid Tumors, Adult, Solid Tumor
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally…
- Conditions
- Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE)
- Trial name
- NCT05228015
- Testing
- IK-930, Osimertinib
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- Ikena Oncology
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe)
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Background: Cancers that spread into the thin tissue lining your lungs (pleura) cause serious illness. They often recur when removed.
- Conditions
- Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant
- Trial name
- NCT05375825
- Testing
- Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Malignant Mesothelioma (MPM)
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
The purpose of this study is to find out whether the combination of avelumab and SBRT is safe and what effect avelumab has on mesothelioma when given in combination with SBRT.
- Trial name
- NCT03399552
- Testing
- Avelumab, Stereotactic Body Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma (MPM)
Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM
Background: Metronomic oral Vinorelbine has efficacy in metastatic NSCLC and malignant Pleural Mesothelioma, but all the studies published thus far were based upon a variety of empirical and possibly suboptimal schedules, with…
- Trial name
- NVB Metro (NCT02555007)
- Testing
- Vinorelbine
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Malignant Pleural Mesothelioma (MPM), Choroidal Nevus
Clinical and Histopathologic Characteristics of BAP1 Mutations
The goal of this protocol is to determine the prevalence of somatic and germline mutations in BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus, primary uveal melanoma (UM), or metastatic UM seen…
- Conditions
- Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM), Metastatic Uveal Melanoma (UM)
- Trial name
- NCT01773655
- Testing
- tumor specimens
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Pleural Mesothelioma (MPM)
A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
A phase Ib study investigating the safety, the immunogenicity and the optimal administration frequency of the S-588210 5-peptide vaccine in MPM patients without progression after pemetrexed-based chemotherapy will be conducted.
- Trial name
- NCT02661659
- Testing
- Multipeptide vaccine S-588210
- Where
- United States
- Sponsor
- University of Chicago
Advanced Malignant Pleural Mesothelioma, MPM
A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
This is a single-arm, open label, two stage, phase II study of dovitinib in patients with advanced Malignant Pleural Mesothelioma (MPM).
- Trial name
- DOVE-M (NCT01769547)
- Testing
- Dovitinib
- Where
- 5 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)